Eli Lilly and Co. has stopped clinical studies for pomaglumetad methionil, or mGlu2/3, for the treatment of schizophrenia. The decision follows analysis of two Phase III studies showing that the drug was unlikely to meet its primary efficacy endpoint. The decision was not based on any safety signals.   “I’m disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness,” said Jan Lundberg, Ph.D., execut...